Additional Independent Research Further Supports Glucose Metabolism as Important COVID-19 Target

HOUSTON, July 29, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a recent publication by an independent research team at the University of Campinas in São Paulo, Brazil demonstrated that SARS-CoV-2 infection is supported by elevated glucose levels and that inhibition of glycolysis with 2-deoxy-D-glucose (“2-DG”) effectively eliminated viral load in vitro.

The release as fetched from its publisher. moleculin.com ↗